We have located links that may give you full text access.
Laser treatment of scars.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.] 1995 August
BACKGROUND: Erythematous and hypertrophic scars may occur after surgical procedures. This paper describes a novel technique for their resolution.
OBJECTIVE: The purpose of this paper is to describe long-term results of treating erythematous, hypertrophic scars with the flashlamp-pumped pulsed dye laser (FLPDL).
METHODS: Forty-eight patients who presented with erythematous/hypertrophic scars were treated with the FLPDL with or without intralesional triamcinolone. Patients were evaluated by physicians on a 25% increment of objective improvement.
RESULTS: Seventy-three percent of scars appearing on the face for less than 1 year totally resolved in an average of 2.3 treatments. Twenty percent of scars on the face for greater than 1 year had a total resolution in 4.4 treatments with an average improvement of 88%. Scars on nonfacial areas for less than 1 year had a 25% incidence of total resolution over an average of 2.5 treatments with an average improvement of 81%. Scars in nonfacial distributions over 1 year of age had a 12% total resolution with an average 62% improvement over 2.2 treatments.
CONCLUSION: The FLPDL is a useful adjuvant in the treatment of erythematous, hypertrophic scars.
OBJECTIVE: The purpose of this paper is to describe long-term results of treating erythematous, hypertrophic scars with the flashlamp-pumped pulsed dye laser (FLPDL).
METHODS: Forty-eight patients who presented with erythematous/hypertrophic scars were treated with the FLPDL with or without intralesional triamcinolone. Patients were evaluated by physicians on a 25% increment of objective improvement.
RESULTS: Seventy-three percent of scars appearing on the face for less than 1 year totally resolved in an average of 2.3 treatments. Twenty percent of scars on the face for greater than 1 year had a total resolution in 4.4 treatments with an average improvement of 88%. Scars on nonfacial areas for less than 1 year had a 25% incidence of total resolution over an average of 2.5 treatments with an average improvement of 81%. Scars in nonfacial distributions over 1 year of age had a 12% total resolution with an average 62% improvement over 2.2 treatments.
CONCLUSION: The FLPDL is a useful adjuvant in the treatment of erythematous, hypertrophic scars.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app